A Nanounit Strategy Disrupts Energy Metabolism and Alleviates Immunosuppression for Cancer Therapy

Area of Science:

• Biomedical Engineering
• Cancer Research
• Immunology

Background:

• Aberrant tumor metabolism fuels cancer growth and creates an immunosuppressive tumor microenvironment (ITM).
• The ITM, characterized by glucose deficiency and lactate accumulation, impairs anti-tumor immune responses.
• Targeting tumor metabolism offers a strategy to overcome immune evasion in cancer.

Purpose of the Study:

• To develop a novel metabolic nanoregulator for synergistic cancer therapy.
• To simultaneously inhibit tumor cell energy supply and alleviate the immunosuppressive tumor microenvironment.
• To enhance anti-tumor immunity and immunotherapy efficacy.

Main Methods:

• A nanoregulator (D/B/CQ@ZIF-8@CS) was synthesized by encapsulating 2-deoxy-d-glucose (2-DG), BAY-876, and chloroquine (CQ) within zeolitic imidazolate framework-8 (ZIF-8).
• The nanoregulator was designed to block aerobic glycolysis, glucose uptake, and autophagy flux in tumor cells.
• The study investigated the nanoregulator's ability to reverse the ITM and augment anti-CTLA-4 immunotherapy.

Main Results:

• The D/B/CQ@ZIF-8@CS nanoregulator effectively blocked tumor cell nutrition and energy supply, reducing lactate production.
• Inhibition of glucose uptake and aerobic glycolysis by the nanoregulator reversed the ITM.
• The strategy led to the functional inactivation of regulatory T cells and enhanced anti-CTLA-4 immunotherapy.

Conclusions:

• Metabolic nanoregulators can simultaneously starve tumor cells and reprogram the tumor microenvironment.
• This dual-action approach offers a promising strategy for synergistic cancer therapy.
• Metabolic intervention combined with immunotherapy presents new avenues for cancer treatment.